{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:28:30Z","timestamp":1781155710590,"version":"3.54.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T00:00:00Z","timestamp":1532649600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1650-8","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T06:09:33Z","timestamp":1532671773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6059-6246","authenticated-orcid":false,"given":"Olga","family":"Kry\u0161t\u016ffkov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Hulejov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He\u0159man F.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ond\u0159ej","family":"Pecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"P\u016ftov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Ekholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid E.","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Vencovsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,27]]},"reference":[{"issue":"9","key":"1650_CR1","doi-asserted-by":"publisher","first-page":"715","DOI":"10.7326\/0003-4819-122-9-199505010-00010","volume":"122","author":"PH Plotz","year":"1995","unstructured":"Plotz PH, Rider LG, Targoff IN, Raben N, O'Hanlon TP, Miller FW. NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med. 1995;122(9):715\u201324.","journal-title":"Ann Intern Med"},{"issue":"6","key":"1650_CR2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/rheumatology\/kep078","volume":"48","author":"H Gunawardena","year":"2009","unstructured":"Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford). 2009;48(6):607\u201312.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1650_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.autrev.2009.03.005","volume":"9","author":"J Ronnelid","year":"2009","unstructured":"Ronnelid J, Barbasso Helmers S, Storfors H, Grip K, Ronnblom L, Franck-Larsson K, Nordmark G, Lundberg IE. Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev. 2009;9(1):58\u201361.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"1650_CR4","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","volume":"70","author":"LA Love","year":"1991","unstructured":"Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine. 1991;70(6):360\u201374.","journal-title":"Medicine"},{"issue":"3","key":"1650_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/08916930600622884","volume":"39","author":"H Yoshifuji","year":"2006","unstructured":"Yoshifuji H, Fujii T, Kobayashi S, Imura Y, Fujita Y, Kawabata D, Usui T, Tanaka M, Nagai S, Umehara H, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity. 2006;39(3):233\u201341.","journal-title":"Autoimmunity"},{"issue":"5","key":"1650_CR6","first-page":"1012","volume":"34","author":"T Matsushita","year":"2007","unstructured":"Matsushita T, Hasegawa M, Fujimoto M, Hamaguchi Y, Komura K, Hirano T, Horikawa M, Kondo M, Orito H, Kaji K, et al. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. J Rheumatol. 2007;34(5):1012\u20138.","journal-title":"J Rheumatol"},{"key":"1650_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","volume":"21","author":"F Mackay","year":"2003","unstructured":"Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2003;21:231\u201364.","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"1650_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1600-0625.2006.00485.x","volume":"16","author":"T Matsushita","year":"2007","unstructured":"Matsushita T, Hasegawa M, Matsushita Y, Echigo T, Wayaku T, Horikawa M, Ogawa F, Takehara K, Sato S. Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases. Exp Dermatol. 2007;16(2):87\u201393.","journal-title":"Exp Dermatol"},{"issue":"12","key":"1650_CR9","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1002\/art.11354","volume":"48","author":"W Stohl","year":"2003","unstructured":"Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, Roschke V, Wu Y, Baker KP, Hilbert DM. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003;48(12):3475\u201386.","journal-title":"Arthritis Rheum"},{"key":"1650_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1196\/annals.1313.004","volume":"1050","author":"JO Pers","year":"2005","unstructured":"Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, Youinou P. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci. 2005;1050:34\u20139.","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"1650_CR11","doi-asserted-by":"publisher","first-page":"R167","DOI":"10.1186\/ar2076","volume":"8","author":"T Vallerskog","year":"2006","unstructured":"Vallerskog T, Heimburger M, Gunnarsson I, Zhou W, Wahren-Herlenius M, Trollmo C, Malmstrom V. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2006;8(6):R167.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1650_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/art.21526","volume":"54","author":"T Matsushita","year":"2006","unstructured":"Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 2006;54(1):192\u2013201.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1650_CR13","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1177\/0961203306071871","volume":"15","author":"A Becker-Merok","year":"2006","unstructured":"Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus. 2006;15(9):570\u20136.","journal-title":"Lupus"},{"issue":"2","key":"1650_CR14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1136\/ard.62.2.168","volume":"62","author":"X Mariette","year":"2003","unstructured":"Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, Kimberly R. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren\u2019s syndrome. Ann Rheum Dis. 2003;62(2):168\u201371.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1650_CR15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.clim.2005.06.016","volume":"117","author":"P Szodoray","year":"2005","unstructured":"Szodoray P, Alex P, Jonsson MV, Knowlton N, Dozmorov I, Nakken B, Delaleu N, Jonsson R, Centola M. Distinct profiles of Sjogren\u2019s syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol. 2005;117(2):168\u201376.","journal-title":"Clin Immunol"},{"issue":"6","key":"1650_CR16","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S","volume":"44","author":"GS Cheema","year":"2001","unstructured":"Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001;44(6):1313\u20139.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1650_CR17","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1136\/ard.2008.091405","volume":"68","author":"O Krystufkova","year":"2009","unstructured":"Krystufkova O, Vallerskog T, Helmers SB, Mann H, Putova I, Belacek J, Malmstrom V, Trollmo C, Vencovsky J, Lundberg IE. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis. 2009;68(6):836\u201343.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1650_CR18","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1002\/art.22865","volume":"56","author":"KB Stone","year":"2007","unstructured":"Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, Domsic R, Ascherman DP. anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 2007;56(9):3125\u201331.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1650_CR19","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/art.24631","volume":"60","author":"TJ Richards","year":"2009","unstructured":"Richards TJ, Eggebeen A, Gibson K, Yousem S, Fuhrman C, Gochuico BR, Fertig N, Oddis CV, Kaminski N, Rosas IO, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum. 2009;60(7):2183\u201392.","journal-title":"Arthritis Rheum"},{"key":"1650_CR20","doi-asserted-by":"publisher","first-page":"648570","DOI":"10.1155\/2013\/648570","volume":"2013","author":"X Cen","year":"2013","unstructured":"Cen X, Zuo C, Yang M, Yin G, Xie Q. A clinical analysis of risk factors for interstitial lung disease in patients with idiopathic inflammatory myopathy. Clin Dev Immunol. 2013;2013:648570.","journal-title":"Clin Dev Immunol"},{"issue":"6","key":"1650_CR21","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/art.10794","volume":"47","author":"I Marie","year":"2002","unstructured":"Marie I, Hachulla E, Cherin P, Dominique S, Hatron PY, Hellot MF, Devulder B, Herson S, Levesque H, Courtois H. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47(6):614\u201322.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1650_CR22","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1093\/rheumatology\/ker282","volume":"50","author":"GO Eilertsen","year":"2011","unstructured":"Eilertsen GO, Van Ghelue M, Strand H, Nossent JC. Increased levels of BAFF in patients with systemic lupus erythematosus are associated with acute-phase reactants, independent of BAFF genetics: a case-control study. Rheumatology (Oxford). 2011;50(12):2197\u2013205.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"1650_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403\u20137.","journal-title":"N Engl J Med"},{"issue":"7","key":"1650_CR24","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344\u20137.","journal-title":"N Engl J Med"},{"issue":"1","key":"1650_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","volume":"43","author":"DA Isenberg","year":"2004","unstructured":"Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, Oddis C, Pilkington C, Plotz P, Scott D, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford). 2004;43(1):49\u201354.","journal-title":"Rheumatology (Oxford)"},{"key":"1650_CR26","first-page":"22","volume-title":"LISREL (version 8.8)","author":"KG J\u00f6reskog","year":"2006","unstructured":"J\u00f6reskog KG, S\u00f6rbom D. LISREL (version 8.8). Lincolnwood: Scientific Software International, Inc; 2006. p. 22\u201369."},{"issue":"2","key":"1650_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1467-9574.2009.00420.x","volume":"63","author":"K Montfort","year":"2009","unstructured":"Montfort K, Mooijaart A, Meijerink F. Estimating structural equation models with nonnormal variables by using transformations. Statistica Nederlandica. 2009;63(2):213\u201326.","journal-title":"Statistica Nederlandica"},{"key":"1650_CR28","first-page":"13","volume-title":"Structural equation modeling: foundation and extension","author":"DW Kaplan","year":"2008","unstructured":"Kaplan DW. Structural equation modeling: foundation and extension. Thousand Oaks: Sage; 2008. p. 13\u201338."},{"key":"1650_CR29","first-page":"93","volume-title":"Principles and practice of structural equation modeling","author":"RB Kline","year":"2005","unstructured":"Kline RB. Principles and practice of structural equation modeling. 2nd ed. New York: Guilford Press; 2005. p. 93\u2013161.","edition":"2"},{"key":"1650_CR30","first-page":"14","volume-title":"HLM 6: hierarchical linear and nonlinear modeling","author":"SW Raudenbush","year":"2004","unstructured":"Raudenbush SW, Bryk AS, Cheong YF, Congon R, duToit M. HLM 6: hierarchical linear and nonlinear modeling. Lincolnwood: Scientific Software International, Inc; 2004. p. 14\u201364."},{"key":"1650_CR31","first-page":"47","volume-title":"Longitudinal Data Analysis","author":"D Hedeker","year":"2006","unstructured":"Hedeker D, Gibbons R. Longitudinal Data Analysis. New Jersey: Wiley; 2006. p. 47."},{"key":"1650_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/acprof:oso\/9780195152968.001.0001","volume-title":"Applied longitudinal data analysis: modeling change and event occurrence","author":"JD Singer","year":"2003","unstructured":"Singer JD, Willett JB. Applied longitudinal data analysis: modeling change and event occurrence. New York: Oxford University Press; 2003. p. 45\u201374."},{"issue":"10","key":"1650_CR33","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1093\/rheumatology\/keq151","volume":"49","author":"P Szodoray","year":"2010","unstructured":"Szodoray P, Alex P, Knowlton N, Centola M, Dozmorov I, Csipo I, Nagy AT, Constantin T, Ponyi A, Nakken B, et al. Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand. Rheumatology (Oxford). 2010;49(10):1867\u201377.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1650_CR34","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2217\/bmm.13.124","volume":"8","author":"QL Peng","year":"2014","unstructured":"Peng QL, Shu XM, Wang DX, Wang Y, Lu X, Wang GC. B-cell activating factor as a serological biomarker for polymyositis and dermatomyositis. Biomark Med. 2014;8(3):395\u2013403.","journal-title":"Biomark Med"},{"issue":"12","key":"1650_CR35","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.3899\/jrheum.140977","volume":"42","author":"N Kobayashi","year":"2015","unstructured":"Kobayashi N, Kobayashi I, Mori M, Sato S, Iwata N, Shigemura T, Agematsu K, Yokota S, Koike K. Increased serum B cell activating factor and a proliferation-inducing ligand are associated with interstitial lung disease in patients with juvenile dermatomyositis. J Rheumatol. 2015;42(12):2412\u20138.","journal-title":"J Rheumatol"},{"issue":"2","key":"1650_CR36","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1136\/ard.60.2.116","volume":"60","author":"R Brouwer","year":"2001","unstructured":"Brouwer R, Hengstman GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A, Grondal G, Hietarinta M, Isenberg D, Kalden JR, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis. 2001;60(2):116\u201323.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1650_CR37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/annrheumdis-2017-211868","volume":"77","author":"JB Lilleker","year":"2018","unstructured":"Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, Oakley P, Benveniste O, Danieli MG, Danko K, et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis. 2018;77(1):30\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1650_CR38","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s100670070030","volume":"19","author":"WA Schmidt","year":"2000","unstructured":"Schmidt WA, Wetzel W, Friedlander R, Lange R, Sorensen HF, Lichey HJ, Genth E, Mierau R, Gromnica-Ihle E. Clinical and serological aspects of patients with anti-Jo-1 antibodies\u2014an evolving spectrum of disease manifestations. Clin Rheumatol. 2000;19(5):371\u20137.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"1650_CR39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/ard.2003.006122","volume":"63","author":"M Fathi","year":"2004","unstructured":"Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004;63(3):297\u2013301.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1650_CR40","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/rheumatology\/ket120","volume":"52","author":"EM McCarthy","year":"2013","unstructured":"McCarthy EM, Lee RZ, Ni Gabhann J, Smith S, Cunnane G, Doran MF, Howard D, O'Connell P, Kearns G, Jefferies CA. Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort. Rheumatology (Oxford). 2013;52(7):1279\u201384.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"1650_CR41","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/art.23678","volume":"58","author":"M Petri","year":"2008","unstructured":"Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, Recta V, Zhong J, Freimuth W. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58(8):2453\u20139.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1650_CR42","first-page":"1256","volume":"35","author":"S Bosello","year":"2008","unstructured":"Bosello S, Youinou P, Daridon C, Tolusso B, Bendaoud B, Pietrapertosa D, Morelli A, Ferraccioli G. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol. 2008;35(7):1256\u201364.","journal-title":"J Rheumatol"},{"issue":"5","key":"1650_CR43","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/art.1780260505","volume":"26","author":"S Yoshida","year":"1983","unstructured":"Yoshida S, Akizuki M, Mimori T, Yamagata H, Inada S, Homma M. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis and rheumatism. 1983;26(5):604\u201311.","journal-title":"Arthritis and rheumatism"},{"issue":"2","key":"1650_CR44","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1172\/JCI114461","volume":"85","author":"FW Miller","year":"1990","unstructured":"Miller FW, Twitty SA, Biswas T, Plotz PH. Origin and regulation of a disease-specific autoantibody response. Antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies. J Clin Invest. 1990;85(2):468\u201375.","journal-title":"J Clin Invest"},{"issue":"9","key":"1650_CR45","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/acr.21716","volume":"64","author":"C Muangchan","year":"2012","unstructured":"Muangchan C, Harding S, Khimdas S, Bonner A, Canadian Scleroderma Research Group, Baron M, Pope J. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res. 2012;64(9):1405\u201314.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"1650_CR46","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10067-015-3139-z","volume":"35","author":"Y Xu","year":"2016","unstructured":"Xu Y, Yang CS, Li YJ, Liu XD, Wang JN, Zhao Q, Xiao WG, Yang PT. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis. Clin Rheumatol. 2016;35(1):113\u20136.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"1650_CR47","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1177\/0961203315604909","volume":"25","author":"DA Roth","year":"2016","unstructured":"Roth DA, Thompson A, Tang Y, Hammer AE, Molta CT, Gordon D. Elevated BLyS levels in patients with systemic lupus erythematosus: associated factors and responses to belimumab. Lupus. 2016;25(4):346\u201354.","journal-title":"Lupus"},{"issue":"2","key":"1650_CR48","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.4049\/jimmunol.181.2.1012","volume":"181","author":"X Li","year":"2008","unstructured":"Li X, Su K, Ji C, Szalai AJ, Wu J, Zhang Y, Zhou T, Kimberly RP, Edberg JC. Immune opsonins modulate BLyS\/BAFF release in a receptor-specific fashion. J Immunol. 2008;181(2):1012\u20138.","journal-title":"J Immunol"},{"issue":"3","key":"1650_CR49","first-page":"740","volume":"66","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Care Res. 2014;66(3):740\u20139.","journal-title":"Arthritis Care Res"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1650-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1650-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1650-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T19:07:16Z","timestamp":1564168036000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1650-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,27]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1650"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1650-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,27]]},"assertion":[{"value":"28 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of the Institute of Rheumatology in Prague and by the local ethics committee at the Karolinska Hospital Nord, Stockholm. Informed consent to participate was obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable as no individual personal data are included.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"158"}}